Tower Research Capital (TRC)’s DataMeds AI MEDS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$21.7K Buy
6,841
+6,163
+909% +$15.1K ﹤0.01% 3750
2026
Q2
$2.1K Buy
+678
New +$3.34K ﹤0.01% 4718
2026
Q1
– Sell
-288
Closed -$5.75K – 5698
2025
Q4
$5.75K Sell
288
-42
-13% -$1.23K ﹤0.01% 4098
2025
Q3
$14.7K Buy
+330
New +$17.4K ﹤0.01% 3583

Other funds holding MEDS

Tower Research Capital (TRC)'s MEDS Position: Q3 2026 in Review

Tower Research Capital (TRC) increased its DataMeds AI (MEDS) stake by 909% in Q3 2026, buying an estimated $15.1K and bringing the position to 6,841 shares worth $21.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3750.

Tower Research Capital (TRC) first reported a position in MEDS in Q3 2025 and has held it in 4 quarters since. 16 funds tracked by Wall St. Rank hold MEDS as of Q3 2026.

  • Tower Research Capital (TRC) held 6,841 shares of DataMeds AI worth $21.7K as of Q3 2026.
  • Tower Research Capital (TRC) bought 6,163 DataMeds AI shares in Q3 2026, an estimated $15.1K.
  • DataMeds AI made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #3750 holding.
  • Tower Research Capital (TRC) first reported a position in DataMeds AI in Q3 2025 and has held it in 4 quarters since.
  • 16 funds tracked by Wall St. Rank held DataMeds AI as of Q3 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.